Abstract
Recently, substantial attention has been focused on cancer treatments using oncolytic viruses, which may result in a paradigm shift in conventional cancer therapy through the use of these viruses either alone or in combination with other therapeutics. Thus far, the cancer-killing mechanism of oncolytic viruses has been dependent on selective viral replication in cancer cells. However, UV-irradiated Sendai virus particles (hemagglutinating virus of Japan envelope; HVJ-E) with membrane fusion activity selectively induce apoptosis in human cancer cells but not non-cancerous cells, although neither viral genome replication nor viral protein synthesis occurs in infected cells. The mechanism of HVJ-E-induced cancer cell killing involves the introduction of viral genome RNA fragments into the cytoplasm via membrane fusion and the subsequent activation of a retinoic acid-inducible gene-I (RIG-I)-like receptor signal, which results in the upregulation of apoptotic genes such as tumor necrosis factor-related apoptosis inducing ligand (TRAIL) and Noxa through the phosphorylation of interferon-regulatory factor (IRF)-3 and -7. In neuroblastoma cells lacking caspase 8, HVJ-E induces programmed necrosis (necroptosis) through the activation of cytoplasmic calcium, which in turn activates calcium-calmodulin-depedent protein kinase to phosphorylate receptorinteracting protein (RIP)-1 and -3. In addition to directly killing cancer, HVJ-E elicits anti-tumor immunity by recruiting immune cells to the tumor microenvironment, facilitating the maturation of dendritic cells, enhancing natural killer (NK) cell activity and ultimately activating killer T cells targeting cancers. Anti-tumor immunity is also achieved via the RIG-I-like receptor signal triggered by cytoplasmic viral RNA fragments, independent of toll-like receptor signaling. Moreover, the fusion protein of HVJ-E acts directly on dendritic cells and macrophages to produce interleukin (IL)-6, which attenuates the function of regulatory T cells. Thus, HVJ-E provides a multi-modal strategy for cancer therapy.
Keywords: Anti-tumor immunity, apoptosis, oncolytic virus, RIG-I-like receptor, sendai virus, viral RNA, virosome.
Graphical Abstract
Current Cancer Therapy Reviews
Title:Multi-modal Anti-cancer Activities Provided by a Non-replicating Sendai Virus Envelope
Volume: 11 Issue: 3
Author(s): Yasufumi Kaneda
Affiliation:
Keywords: Anti-tumor immunity, apoptosis, oncolytic virus, RIG-I-like receptor, sendai virus, viral RNA, virosome.
Abstract: Recently, substantial attention has been focused on cancer treatments using oncolytic viruses, which may result in a paradigm shift in conventional cancer therapy through the use of these viruses either alone or in combination with other therapeutics. Thus far, the cancer-killing mechanism of oncolytic viruses has been dependent on selective viral replication in cancer cells. However, UV-irradiated Sendai virus particles (hemagglutinating virus of Japan envelope; HVJ-E) with membrane fusion activity selectively induce apoptosis in human cancer cells but not non-cancerous cells, although neither viral genome replication nor viral protein synthesis occurs in infected cells. The mechanism of HVJ-E-induced cancer cell killing involves the introduction of viral genome RNA fragments into the cytoplasm via membrane fusion and the subsequent activation of a retinoic acid-inducible gene-I (RIG-I)-like receptor signal, which results in the upregulation of apoptotic genes such as tumor necrosis factor-related apoptosis inducing ligand (TRAIL) and Noxa through the phosphorylation of interferon-regulatory factor (IRF)-3 and -7. In neuroblastoma cells lacking caspase 8, HVJ-E induces programmed necrosis (necroptosis) through the activation of cytoplasmic calcium, which in turn activates calcium-calmodulin-depedent protein kinase to phosphorylate receptorinteracting protein (RIP)-1 and -3. In addition to directly killing cancer, HVJ-E elicits anti-tumor immunity by recruiting immune cells to the tumor microenvironment, facilitating the maturation of dendritic cells, enhancing natural killer (NK) cell activity and ultimately activating killer T cells targeting cancers. Anti-tumor immunity is also achieved via the RIG-I-like receptor signal triggered by cytoplasmic viral RNA fragments, independent of toll-like receptor signaling. Moreover, the fusion protein of HVJ-E acts directly on dendritic cells and macrophages to produce interleukin (IL)-6, which attenuates the function of regulatory T cells. Thus, HVJ-E provides a multi-modal strategy for cancer therapy.
Export Options
About this article
Cite this article as:
Kaneda Yasufumi, Multi-modal Anti-cancer Activities Provided by a Non-replicating Sendai Virus Envelope, Current Cancer Therapy Reviews 2015; 11 (3) . https://dx.doi.org/10.2174/1573394712666160128201847
DOI https://dx.doi.org/10.2174/1573394712666160128201847 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Related Books
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current Drugs and Potential Future Neuroprotective Compounds for Parkinson’s Disease
Current Neuropharmacology Potential Role of (-)-Epigallocatechin-3-Gallate (EGCG) in the Secondary Prevention of Alzheimer Disease
Current Drug Targets Current Constructs and Targets in Clinical Development for Antibody- Based Cancer Therapy
Current Drug Targets Neurodegenerative Pathways in Alzheimer’s Disease: A Review
Current Neuropharmacology Identification of Functional Peptides from Natural and Synthetic Products on Their Anticancer Activities by Tumor Targeting
Current Medicinal Chemistry Endoplasmic Reticulum Protein Quality Control in Neurodegenerative Disease: The Good, the Bad and the Therapy
Current Medicinal Chemistry Peripheral Neuropathy Induced by Paclitaxel: Recent Insights and Future Perspectives
Current Neuropharmacology Proteasome Regulators: Activators and Inhibitors
Current Medicinal Chemistry From Surface to Nuclear Receptors: The Endocannabinoid Family Extends its Assets
Current Medicinal Chemistry Preface
Current Angiogenesis (Discontinued) Therapeutic Potential of Hammerhead Ribozymes in the Treatment of Hyper-Proliferative Diseases
Current Pharmaceutical Biotechnology Molecular Mechanisms of Action of Gas1 and its Possible Therapeutic Applications
Current Signal Transduction Therapy Diabetes Mellitus: Channeling Care through Cellular Discovery
Current Neurovascular Research Recent Patents in Circulating Cell-Free Tumor DNA as Biomarker in Cancer
Recent Patents on Biomarkers Immunology Behind Tumors: A Mini Review
Current Cancer Therapy Reviews Nongenomic Actions of Thyroid Hormones: From Basic Research to Clinical Applications. An Update
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Electrochemical Study of Ellipticine Interaction with Single and Double Stranded Oligonucleotides
Anti-Cancer Agents in Medicinal Chemistry Paullones as Inhibitors of Protein Kinases
Current Topics in Medicinal Chemistry Perspectives of Fullerenes, Dendrimers, and Heterocyclic Compounds Application in Tumor Treatment
Recent Patents on Nanomedicine Clostridial Neurotoxins: Mode of Substrate Recognition and Novel Therapy Development
Current Protein & Peptide Science